Tags : Oxford BioTherapeutics


Oxford BioTherapeutics Licenses WuXi Biologics’ WuXiBody Platform for Five Bispecific

Shots: Wuxi  to receive upfront, $450M milestone and royalties on sales from Oxford BioTherapeutics. Oxford to get rights for WuXi Biologics’ WuXiBody platform to develop and commercialize five Bispecific Abs for cancer The focus of the agreement is to develop cancer therapies by combining WuXiBody platform with PDL1 Ab with reduction in cost & risk rates WuXiBody platform is a bispecific […]Read More